FDA Approves Vyalev for Advanced Parkinson Disease
By Lori Solomon HealthDay Reporter
TUESDAY, Oct. 22, 2024 -- The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced Parkinson disease (PD).
Vyalev is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced PD and allows for personalized dosing throughout the day based on individual needs. The manufacturer, AbbVie, says coverage for Medicare patients is expected in the second half of 2025.
The approval was supported by a pivotal phase 3, 12-week study that compared the efficacy of a continuous subcutaneous infusion of Vyalev to oral immediate-release carbidopa/levodopa (CD/LD IR), as well as a 52-week, open-label study that evaluated the long-term safety and efficacy of Vyalev. The pivotal study showed patients receiving Vyalev had superior improvement in motor fluctuations, with increased "on" time without troublesome dyskinesia and decreased "off" time compared with oral CD/LD IR. The majority of adverse reactions with Vyalev were nonserious and mild or moderate in severity, including most frequently (≥10 percent and greater than CD/LD IR incidence) infusion site events, hallucinations, and dyskinesia.
"Due to the progressive nature of the disease, oral medications are eventually no longer as effective at motor symptom control and surgical treatment may be required," Robert A. Hauser, M.D., from the Parkinson's and Movement Disorder Center at the University of South Florida in Tampa, said in a statement. "This new, nonsurgical regimen provides continuous delivery of levodopa morning, day, and night."
Approval of Vyalev was granted to AbbVie.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Common Medications Tied to Older Age at Onset of Parkinson Disease
FRIDAY, April 25, 2025 -- Multiple common medications are associated with a considerable delay of Parkinson disease (PD) symptom onset, according to a study published online March...
AAN: Tavapadon as Adjunct to Levodopa Ups Daily ON Time in Parkinson Disease
TUESDAY, April 8, 2025 -- For patients with Parkinson disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist tavapadon as an adjunct to...
Globally, 25.2 Million Projected to Be Living With Parkinson Disease in 2050
MONDAY, March 10, 2025 -- The prevalence of Parkinson disease is projected to increase through 2050, according to a study published online March 5 in The BMJ. Using data from the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.